Skip to main content

Table 2 Patient demographics and tumor characteristics in the fractionated BNCT clinical trial

From: Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor

Patient no. Age Sex Primary site Histopathology Accumulated dose of prior RT (Gy) Recurrent stage Tumor diameter (cm)
1 68 M Hypopharynx SCC 136.4 in 2 courses T1N2a 4
2 67 M Tongue SCC 66 T2N2a 9.5
3 49 F Nasal cavity Sinonasal carcinoma 120 in 2 courses T4N0 5
4 71 M Gingiva SCC 66 T4N0 7.5
5 46 M Nasopharynx Undifferentiated ca 136 in 2 courses T4N0 3.9
6 58 F Nasopharynx Non-keratinizing ca 122 in 2 courses T3N0 2.5
7 57 M Tongue SCC 70 T3N0 4.5
8 52 M Tongue SCC 70 T4aN0 5.3
9 54 M Maxillary sinus SCC 70 T3N0 8.9
10 54 M Tongue SCC 63 T0N2b 6.0
11 48 M Tongue Spindle cell sarcoma 107 in 2 courses T4bN0 6.0
12 74 M Maxillary sinus SCC 105 in 2 courses T2N0 3.5
13 51 M Parotid gland Adenocarcinoma 136 in 2 courses T4N0 5.8
14 56 M Buccal mucosa SCC 125.9 in 2 courses T1N0 0.9
15 40 M Hypopharynx SCC 95 in 2 courses T3N0 4.7
16 59 M Nasopharynx Non-keratinizing ca 136 in 2 courses T3N0 3.9
17 62 M Buccal mucosa SCC 64 T4aN0 6.4
  1. BNCT boron neutron capture therapy, SCC squamous cell carcinoma